Therefore, FGF23 level can be one of the candidate new markers, because it reflects the progression of CKD-MBD, can be easily followed up longitudinally from the early stages of CKD, and can predict outcomes. The gene discussed is FGF23; the disease is Marchiafava-Bignami disease.